Witt, S H
Streit, F
Jungkunz, M
Frank, J
Awasthi, S
Reinbold, C S
Treutlein, J
Degenhardt, F
Forstner, A J
Heilmann-Heimbach, S
Dietl, L
Schwarze, C E
Schendel, D
Strohmaier, J
Abdellaoui, A
Adolfsson, R
Air, T M
Akil, H
Alda, M
Alliey-Rodriguez, N
Andreassen, O A
Babadjanova, G
Bass, N J
Bauer, M
Baune, B T
Bellivier, F
Bergen, S
Bethell, A
Biernacka, J M
Blackwood, D H R
Boks, M P
Boomsma, D I
Børglum, A D
Borrmann-Hassenbach, M
Brennan, P
Budde, M
Buttenschøn, H N
Byrne, E M
Cervantes, P
Clarke, T-K
Craddock, N
Cruceanu, C
Curtis, D
Czerski, P M
Dannlowski, U
Davis, T
de Geus, E J C
Di Florio, A
Djurovic, S
Domenici, E
Edenberg, H J
Etain, B
Fischer, S B
Forty, L
Fraser, C
Frye, M A
Fullerton, J M
Gade, K
Gershon, E S
Giegling, I
Gordon, S D
Gordon-Smith, K
Grabe, H J
Green, E K
Greenwood, T A
Grigoroiu-Serbanescu, M
Guzman-Parra, J
Hall, L S
Hamshere, M
Hauser, J
Hautzinger, M
Heilbronner, U
Herms, S
Hitturlingappa, S
Hoffmann, P
Holmans, P
Hottenga, J-J
Jamain, S
Jones, I
Jones, L A
Juréus, A
Kahn, R S
Kammerer-Ciernioch, J
Kirov, G
Kittel-Schneider, S
Kloiber, S
Knott, S V
Kogevinas, M
Landén, M
Leber, M
Leboyer, M
Li, Q S
Lissowska, J
Lucae, S
Martin, N G
Mayoral-Cleries, F
McElroy, S L
McIntosh, A M
McKay, J D
McQuillin, A
Medland, S E
Middeldorp, C M
Milaneschi, Y
Mitchell, P B
Montgomery, G W
Morken, G
Mors, O
Mühleisen, T W
Müller-Myhsok, B
Myers, R M
Nievergelt, C M
Nurnberger, J I
O'Donovan, M C
Loohuis, L M O
Ophoff, R
Oruc, L
Owen, M J
Paciga, S A
Penninx, B W J H
Perry, A
Pfennig, A
Potash, J B
Preisig, M
Reif, A
Rivas, F
Rouleau, G A
Schofield, P R
Schulze, T G
Schwarz, M
Scott, L
Sinnamon, G C B
Stahl, E A
Strauss, J
Turecki, G
Van der Auwera, S
Vedder, H
Vincent, J B
Willemsen, G
Witt, C C
Wray, N R
Xi, H S
,
,
,
Tadic, A
Dahmen, N
Schott, B H
Cichon, S
Nöthen, M M
Ripke, S
Mobascher, A
Rujescu, D
Lieb, K
Roepke, S
Schmahl, C
Bohus, M
Rietschel, M
Article History
Received: 16 February 2017
Accepted: 10 April 2017
First Online: 20 June 2017
Competing interests
: JIN Jr is an investigator for Assurex and a consultant for Janssen. AT has received consultancy fees from Janssen and Novartis. The remaining authors declare no conflict of interest.